Form 4: ATAI Life Sciences N.V. Reports Sale of Compass Pathways Shares

ATAI Life Sciences N.V. reports the sale of 2,660,000 Ordinary Shares of COMPASS Pathways plc at $6.05 per share on September 26, 2024.

Summary

• ATAI Life Sciences N.V., a significant shareholder of COMPASS Pathways plc, filed a Form 4 on September 27, 2024.
• The report details a transaction on September 26, 2024, where ATAI Life Sciences N.V. disposed of 2,660,000 Ordinary Shares at a price of $6.05 per share.
• Following the transaction, ATAI Life Sciences N.V. indirectly owns 6,905,774 Ordinary Shares through its wholly-owned subsidiary, ATAI Life Sciences AG.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports a transaction without indicating positive or negative implications.

Industry Context

This transaction reflects a change in ATAI Life Sciences' investment position in COMPASS Pathways, a company focused on mental health treatment. The sale could be due to various factors, including portfolio rebalancing or strategic considerations by ATAI.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the underlying reasons for the sale.
• However, large shareholders adjusting their positions is a common occurrence in the biotech and pharmaceutical industries.
• Comparable situations might involve venture capital firms or other large investors reducing their stakes in publicly traded companies after a certain period or following specific milestones.

Key Dates